Shift Bioscience raises £12.5m in seed funding led by BGF to advance cell simulation platform
The seed round was led by BGF with participation from F-Prime Capital, Kindred Capital, and Jonathan Milner.
Shift Bioscience is a biotechnology company based in Cambridge that uses generative artificial intelligence models to understand how gene activation can reverse the aging process.
Shift Bioscience has secured £12.5m in a seed financing round led by BGF. The round also saw participation from existing backers F-Prime Capital, Kindred Capital, and Jonathan Milner. The capital will be directed towards advancing the company's artificial intelligence cell simulation platform and expanding its intellectual property portfolio. The new injection of funds brings the company's total capital raised to date to £14m.
From the founder
"Our technology is addressing the current limitations of cellular reprogramming for treatment of age-related illnesses, "
Daniel Ives
CEO at Shift Bioscience
Investor perspective
"We’re excited to be backing a British company at the forefront of developing a new class of regenerative medicines. Combining machine learning with lab-based biology, Shift’s well-developed platform represents a significant opportunity to address the growing challenges of treating age-related disease and illnesses."
Tim Rea
head of early stage, BGF
Use of funds
- 01Continue product development
- 02Fund research and development
- 03Build out infrastructure
Investors
Categories
About the company
Shift Bioscience
Shift Bioscience uses generative artificial intelligence models to understand how gene activation can reverse the aging process.